←back to thread

Goldman Sachs asks in biotech Report: Is curing patients a sustainable business? (2018)

(www.cnbc.com)
249 points randycupertino | 1 comments | 16 Nov 25 23:01 UTC | HN request time: 0.194s | source
Show context
garyfirestorm ◴[17 Nov 25 00:39 UTC] No.45949879[source]▶
Maybe the insurance should pay substantial amount for drugs/treatment AFTER the patient is cured completely
replies(1): >>45949901 #
1. mattmaroon ◴[17 Nov 25 00:43 UTC] No.45949901[source]▶
That’s sort of the case. Gilead’s cure for Hep C (cited in the article) costs more than treating it.